On Thursday, U.S. Sens. Elizabeth Warren (D-MA) and Cory Gardner (R-CO) announced plans to introduce legislation to let states enact their own marijuana laws without federal interference, a proposal that President Trump told Gardner he supports.
House members are filing a companion bill.
Here’s what other lawmakers and advocates are saying about the bill…
U.S. Sen. Michael Bennet (D-CO):
Joined @SenCoryGardner to introduce STATES Act to provide more certainty to patients, businesses, & consumers in CO. Congress needs to join 21st century on marijuana regulation. This bill even more important since AG Sessions upended the will of our state by rescinding Cole Memo.
— Michael Bennet (@SenBennetCO) June 7, 2018
U.S. Sen. Catherine Cortez Masto (D-NV):
NV voters have made it clear that they favor the regulation & taxation of marijuana in the state. The states who legalize & regulate marijuana should be respected. That's why I'm proud to cosponsor @SenWarren @SenCoryGardner's #STATESAct to ensure they are https://t.co/dvHlbhA7BB
— Senator Cortez Masto (@SenCortezMasto) June 7, 2018
Congresswoman Barbara Lee (D-CA):
It’s time to finally end the failed #WarOnDrugs. Proud to stand with @SenWarren & @SenCoryGardner in support of the bipartisan, bicameral #STATESact, which would prohibit federal interference in state cannabis laws. https://t.co/vn58W1xM3U
— Rep. Barbara Lee (@RepBarbaraLee) June 7, 2018
Congresswoman Diana DeGette (D-CO):
Coloradans voted for responsible marijuana legalization, and our state is better off because of it. That's why I'm supporting the #STATESAct, to ensure residents are protected from the federal government's meddling into these freedoms within our borders. https://t.co/VtBclymSOS pic.twitter.com/M3VCh51UBK
— Rep. Diana DeGette (@RepDianaDeGette) June 7, 2018
Officials with Competitive Enterprise Institute, Americans for Tax Reform, Taxpayers Protection Alliance and other groups:
“Though we vary in our opinions on marijuana legalization, the signatories to this letter are in strong accord when it comes to the matter of the level of government to which this question should be left. We believe the STATES Act appropriately addresses the conflict between state and federal marijuana laws without asking Congress to take a stance on whether marijuana should be legalized—Congress need only get out of the way of state legislatures and their voters, who are best positioned to decide questions about marijuana legalization. As noted, the undersigned groups believe this right must be restored to the states.”
NORML Political Director Justin Strekal:
“With the introduction of The STATES Act by Senators Warren and Gardner, the movement to end the federal government’s failed policy of cannabis criminalization has truly become a bipartisan effort. The majority of states now regulate marijuana use and more than six out of ten voters endorse legalizing the plant’s use by adults, making it time for the federal government to no longer stand in the way of this progress at the state level. President Trump made a commitment to Senator Gardner that he would support a federalist approach to state marijuana laws. Now Congress must do its part and swiftly move forward on this bipartisan legislation that explicitly provides states with the authority and autonomy to set their own marijuana policies absent the fear of federal incursion from a Justice Department led by militant cannabis prohibitionist Attorney General Jeff Sessions.”
Don Murphy, conservative outreach director for the Marijuana Policy Project:
“The STATES Act is the most significant piece of marijuana-related legislation ever introduced in Congress. With its bipartisan backing in the Senate, it symbolically signals the eventual end of marijuana prohibition at the federal level. This legislation reflects the position President Trump took on marijuana policy during his campaign, and it comes shortly on the heels of the positive comments he made to Sen. Gardner. The president has a unique opportunity to get behind historic legislation that enjoys solid support on both sides of the political spectrum. While we look forward to the day when there is full acceptance of cannabis at the federal level, we heartily embrace the states’ rights approach proposed by this bill. As an organization, we have been at the forefront of changing state marijuana laws for more than 20 years. It is time for those laws to be respected by and protected from the federal government.”
Jolene Forman, staff attorney at the Drug Policy Alliance:
“The STATES Act represents a landmark moment in the movement to end the decades-long war on marijuana,” said. It creates a workable framework for approaching the future of marijuana policy. “The STATES Act is a first step toward ending the harms of marijuana prohibition. This bipartisan proposal clears the way for states to develop their own marijuana policies without fear of federal intervention. This will give states more opportunity to restore communities that have borne the brunt of the drug war and mass criminalization.
Inimai Chettiar, director of the Brennan Center’s Justice program:
“This new bill introduced by Senators Warren and Gardner safeguards states’ ability to set their own reasonable policies about marijuana against the punitive and ineffective approaches preferred by Attorney General Jeff Sessions. In the face of outdated federal policy, this bill defends the ability and responsibility of states to create and test the best marijuana policies for the American people, and will decrease the number of people in our country who are unnecessarily incarcerated.”
Veterans Cannabis Project Founder and Executive Director Nick Etten:
“This bill is an important sign of bipartisan respect for the will of voters across the country, but it does nothing to help the millions of veterans who rely on a federal VA health system that bans veterans from access to state-legal medical cannabis. Millions of veterans want legal access to medical cannabis as a treatment option and that won’t be possible until Congress and President Trump change federal law to remove cannabis from its current Schedule 1 classification.”
New Federalism Fund:
“We applaud Senator Gardner, Senator Warren, Congressman Joyce, Congressman Blumenauer, and the rest of the cosponsors for their bipartisan leadership on the STATES Act. Conflicts between federal and state law are creating untenable issues for the state-licensed and regulated cannabis industry. The STATES ACT amends the Controlled Substances Act to bring federal drug policy back into alignment with the 10th Amendment, allowing each state to determine the best cannabis policy for their citizens. This is as the Founders would have intended, making the STATES Act an important step towards a humane and constitutional federal cannabis policy.”
National Sheriffs’ Association, Major County Sheriffs’ Association, Major Cities Chiefs Association, National Narcotics Officers’ Associations’ Coalition and other law enforcement groups:
“The fact is, gangs and cartels have been making liberal use of legalization to provide cover for their illegal activities. These gangs have ties to Mexican, Cuban, Vietnamese, and Russian cartels. The gangs often purchase homes in residential neighborhoods, wire in extra electricity and water capacity, and convert them into multi-million dollar grow houses in suburban neighborhoods. These gangs are also trafficking in other illegal drugs, organized crime, and prostitution. Crime has been steadily increasing in Colorado in all categories since legalization, including violent crimes.”
Smart Approaches to Marijuana’s Kevin Sabet:
“Four years ago, as a member of the House, Cory Gardner voted against these very same provisions. Now that the pot industry has expanded in Colorado, normalizing use and advertising THC-laced candies to youth, he is singing a different tune. If enacted, this bill would pave the way for the commercialization of the marijuana industry and the creation of the next Big Tobacco. It is a shame that Senator Gardner has chosen to put political donations and expediency ahead of public health and safety. We are seeing communities across the country fight back and SAM applauds New Hampshire, Connecticut, Vermont, and other states who have recently rejected Big Marijuana. We won’t stop amplifying the voices of families and individuals affected by these lax policies.”
Photo courtesy of Chris Wallis // Side Pocket Images.
Marijuana Policy Project Welcomes New Executive Director
The Marijuana Policy Project (MPP), the nation’s best-funded cannabis advocacy group, has named long-time social justice reform advocate Steve Hawkins as its next executive director.
Hawkins, who previously served as the executive director of the National Coalition to Abolish the Death Penalty (NCADP) and executive vice president of the NAACP, will assume responsibility for MPP’s national legalization advocacy efforts just months before a number of states vote to enact their own legal systems.
The decision was made after a “months-long candidate search that included several exceptionally qualified candidates,” MPP said in a press release.
“We are still battling the effects of decades of anti-marijuana legislation and propaganda in this country,” Hawkins told Marijuana Moment. “Huge strides have been made when it comes to setting the record straight, but our work is far from over and there is still a lot of misinformation out there that needs to be addressed.”
“Fundraising and maintaining momentum is also a core challenge for the movement, which is in some ways a victim of its own success. Thanks to the major gains it has made in recent years, many people think legalization is inevitable and that their donations are no longer needed or that they don’t need to take the time to write their elected officials. These laws are not going to change themselves and there is more need than ever for resources and engagement to support federal and state-level reform efforts.”
Hawkins’s experience running successful criminal justice reform campaigns—including a bipartisan effort to end capital punishment for juveniles during his time at the NCADP—made him an apt candidate to spearhead the fight to end prohibition, Troy Dayton, chair of MPP’s board of directors, said in a statement.
“Steve has a strong track record in the field of criminal justice reform, and he knows how to build a movement toward meaningful social change,” Dayton said. “We were not only impressed by his expertise and experience, but also his strong convictions regarding the injustice of marijuana prohibition.”
“The country is moving in the right direction on marijuana policy, but there is still a lot of work to be done.”
Hawkins also previously held leadership positions at Amnesty International and the Coalition for Public Safety.
He told Marijuana Moment that his three decades of experience “defending civil and human rights” has informed his belief that we should “bring an end to marijuana prohibition, which has had a hugely detrimental impact, especially to communities of color,” and that we should “replace it with a more sensible system of regulation.”
“I also believe it is critical we ensure those populations that were so negatively impacted by prohibition are able to participate in and experience the positive impacts of such a regulated system.”
At MPP, Hawkins will succeed Rob Kampia, who late last year left the organization he founded in 1995 to start a for-profit cannabis policy consulting firm called the Marijuana Leadership Campaign. Kampia’s departure was announced shortly after sexual misconduct allegations against him resurfaced amid the #MeToo movement.
Kampia offered some words of advice for the next person to occupy his former seat in a phone interview with Marijuana Moment:
“View yourself as a fundraiser who has to engage in transactional fundraising with the marijuana industry in part, and view yourself as needing to come up with a smart, strategic plan for lobbying in state legislatures rather than doing ballot initiatives where no one else is going to touch it. Do not view yourself as a spokesperson.”
Or in other words, less of a focus on talk, and more on action.
MPP named Matthew Schweich as the interim executive director while the group scouted for a replacement. Scweich will now serve as MPP’s deputy director overseeing marijuana reform initiatives in Michigan and Utah.
In a statement, MPP board member Joby Pritzker said Schweich “provided critical leadership during a challenging transition period for MPP.”
“He maintained the effectiveness of our advocacy operations, managed our fundraising efforts, and oversaw ballot initiative campaigns in multiple states, while at the same time leading our staff and assisting the board with the executive director search.”
The past few years have seen a number of leadership changeups at national pro-legalization groups.
NORML brought on Erik Altieri as executive director in 2016 after Allen St. Pierre left the organization following 11 years of service. And last year, the Drug Policy Alliance announced that it had hired Maria McFarland Sánchez-Moreno, who worked on international and domestic drug policies issues for 13 years at the Human Rights Watch, as the new executive director to replace retiring founder Ethan Nadelmann.
While the objective at all of these groups—promoting equitable drug policy reform in the United States—has remained the same, the nature of the movement has evolved. A majority of states have now legalized cannabis for medical or recreational purposes, and though state-level reform efforts continue, calls for change at the federal level are increasingly resonant.
That is to say, these new executive directors will face a different set of challenges than their predecessors did.
Photo courtesy of Beloit College.
UN Launches First-Ever Full Review Of Marijuana’s Status Under International Law
For the first time ever, the United Nations (UN) is launching an in-depth review of whether marijuana is properly classified under international drug treaties.
In a related development, the UN’s World Health Organization (WHO) has announced that cannabidiol (CBD), a compound in marijuana that is increasingly used for medical purposes, does not warrant being controlled under the global agreements.
“The Committee recommended that preparations considered to be pure CBD should not be scheduled within the International Drug Control Conventions,” WHO Director-General Tedros Adhanom Ghebreyesus wrote in a letter announcing the moves. “The Committee concluded that there is sufficient evidence to proceed to a Critical Review” of marijuana, hashish, cannabis extracts and THC.
That broader review is set for November, and follows the results of an initial pre-review conducted by WHO’s Expert Committee on Drug Dependence (ECDD) in June.
“A pre-review is the first step of the ECDD’s assessment process, where it is determined whether there is enough robust scientific information to proceed to the next step, called a critical review,” an explanatory document accompanying the new letter reads. “This initial evaluation is also an opportunity to identify gaps in the available scientific data. A critical review is carried out when there is sufficient scientific evidence to allow the ECDD to make informed an recommendation that the substance be placed under international control, or if its level of control should be changed.”
The reviews include analyses of the chemistry, pharmacology, toxicology, epidemiology and therapeutic use of the substances.
If the UN ultimately decides to change marijuana’s status under international law, it would trigger a review on U.S. scheduling, according to provisions of the Controlled Substances Act.
“Thankfully the World Health Organization has accepted the challenge of evaluating the placement of cannabis in the 1962 Single Convention treaty,” Michael Krawitz of Veterans for Medical Cannabis Access told Marijuana Moment. “Cannabis placement in the treaty was done in the absence of scientific evaluation and has provided the basis for a moral campaign against drugs by the USA for many decades. Since our work on medical access to cannabis has been based upon scientific inquiry we know that any rational assessment of the evidence leads the observer to understand cannabis indeed has proven medicinal value and, compared to other medicines, has profoundly fewer negative side effects.”
Here’s what the UN experts have determined so far:
“There are no case reports of abuse or dependence relating to the use of pure CBD. No public health problems have been associated with CBD use,” an annex attached to Ghebreyesus’s letter reads, noting that research has shown it to be effective in treating epilepsy. “CBD has been found to be generally well tolerated with a good safety profile.”
“Cannabidiol (CBD) is not specifically listed in the schedules of the 1961, 1971 or 1988 United Nations International Drug Control Conventions… There is no evidence that CBD as a substance is liable to similar abuse and similar ill-effects as substances in the 1961 or 1971 Conventions such as cannabis or THC, respectively. The Committee recommended that preparations considered to be pure CBD should not be scheduled.”
When it comes to whole-plant marijuana and resin, ECDD’s pre-review found that while “adverse effects” are possible and that cannabis can cause physical dependence, its current categorization in international treaties “may not appear to be consistent with the criteria.”
“Several countries permit the use of cannabis for the treatment of medical conditions such as back pain, sleep disorders, depression, post-injury pain, and multiple sclerosis,” the document says. “The evidence presented to the Committee did not indicate that cannabis plant and cannabis resin were liable to produce ill-effects similar to these other substances that are in Schedule IV of the 1961 Convention on Narcotic Drugs. The inclusion of cannabis and cannabis resin in Schedule IV may not appear to be consistent with the criteria for Schedule IV.”
“The Committee concluded that there is sufficient evidence to proceed to critical review of cannabis plant and cannabis resin at a future ECDD meeting and explore further the appropriateness of their current scheduling within the 1961 Convention.”
With respect to extracts and tinctures of cannabis, the committee similarly identified health issues associated with consumption, but said “there is limited evidence of a withdrawal syndrome upon abrupt cessation.”
The committee also looked at THC itself and isomers of THC, and recommended that both be subject to critical reviews in November.
Ghebreyesus’s letter is addressed to UN Secretary-General Antonio Guterres, who will be the ultimate recipient of WHO’s recommendations on cannabis and related extracts and compounds following the review.
Guterres was prime minister of Portugal when that nation decriminalized all drugs, a move he touted last year in an address to the UN’s Commission on Narcotic Drugs. After the critical reviews are in, that body will vote on whether to alter cannabis’s status under the international treaties.
Marijuana Moment Patreon supporters can see the full text of the new WHO letter on cannabis below:
North Dakota Marijuana Legalization Measure Qualifies For November Ballot
North Dakotans voted to approve medical cannabis two years ago, and now they will get the chance to decide on full marijuana legalization this November.
Activists collected a sufficient number of signatures to qualify a ballot measure that would allow adults over 21 to use and grow marijuana, the secretary of state’s office determined on Monday.
(Marijuana Moment’s editor provides some content to Forbes via a temporary exclusive publishing license arrangement.)
Photo courtesy of Philip Steffan.